MedTrace Logo

Genetic Variants in Egyptian Patients Receiving HCQ(Hydroxychloroquine)

NCT03180190 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-06-09

No results posted yet for this study

Summary

Hydroxychloroquine(HCQ)play major role in management of many rheumatic diseases.

Retinal toxicity from HCQ is serious side effect because even after the drug drug is discontinued, there is little if any visual recovery. For this reason, regular screening for retinal toxicity is recommended to detect early retinopathy and discontinue the therapy.

Cytochrome P450 (CYP) enzymes play major roles in drug metabolism. Certain single-nucleotide polymorphisms(SNPs) in CYP genes may have a large impact on CYP enzyme activity.Polymorphisms in the cytochrome P450 gene might influence blood concentration some patients have a genetic predisposition to HCQ toxicity (e.g.,from abnormalities in the ABCA4 gene)Which is not studied previously among Egyptian population

Conditions

Interventions

DRUG

Hydroxychloroquine Oral Tablet

slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by * Perimetry using Octopus perimeter and utilizing 24-2 test strategy, * Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-28
Primary Completion
2018-06-28
Completion
2018-07-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03180190 on ClinicalTrials.gov